Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGA-360
- Development stage
- Unknown
- Lead developer
- Nobelpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SGA-360 is an orally bioavailable small molecule antagonist of the C-X-C motif chemokine receptor 2 (CXCR2), developed by Second Genome for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis. Identified via a proprietary microbiome discovery platform, SGA-360 targets the migration of neutrophils into the gut wall, a key driver of mucosal inflammation and tissue damage in IBD patients. By blocking the CXCR2-mediated signaling pathway, the compound aims to provide a targeted anti-inflammatory effect. The program was part of a significant strategic collaboration between Second Genome and Gilead Sciences focused on identifying new targets and drug candidates for inflammation and fibrosis.
02
Targets
AHR (Aryl hydrocarbon receptor)ESR1 (ERα)ESR2 (ERβ)CXCR2 (C-X-C Motif Chemokine Receptor 2)
Beyond the preview
Go deeper on SGA-360.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGA-360.